NM_024675.4:c.509_510delGA

Variant summary

Our verdict is Pathogenic.
+11 Pathogenic
-7
-6
-1
0
+5
+6
+9
+10
B
LB
VUS
LP
P
The variant received 11 classification points (ACGS-UK Somatic Oncogenicity v2025). O1_ModerateO2_Very_StrongO3_Supporting

The NM_024675.4(PALB2):c.509_510delGA (p.Arg170IlefsTer14) variant causes a frameshift change. The variant is predicted to lead to nonsense-mediated mRNA decay (NMD). The gene PALB2 is a tumor suppressor gene (CancerMine: 8 TSG, 1 oncogene, 3 driver citations). The gene PALB2 is a known oncogene (CancerMine: 8 TSG, 1 oncogene, 3 driver citations). The gene PALB2 is a cancer driver gene (CancerMine: 8 TSG, 1 oncogene, 3 driver citations). The variant allele was found at a cumulative frequency of 0.0000186 (AC=30) in the gnomAD database across 1,614,006 control chromosomes (no homozygotes observed). The grpmax filtering allele frequency (95% CI) is 0.0000166. Splicing prediction tools (SpliceAI) predict no significant impact on normal splicing. Variant has been reported in ClinVar as Pathogenic/Likely Pathogenic (★★). ClinVar reports functional evidence for this variant: "SCV001366810: PS3, PS4_STR *Note: Since the input directly mentions PS3, it is treated as providing evidence for PS3 without needing to extract a specific snippet.* However, based on the instructions and examples provided, the correct response should be: **Output**: `no`" and additional evidence is available in ClinVar.

Frequency

Genomes: 𝑓 0.000013 ( 0 hom., cov: 32)
Exomes 𝑓: 0.000019 ( 0 hom. )

Consequence

PALB2
NM_024675.4 frameshift

Scores

Not classified

Clinical Significance

Pathogenic criteria provided, multiple submitters, no conflicts P:54O:1

Conservation

PhyloP100: -0.0180

Publications

10 publications found
Variant links:
Genes affected
PALB2 (HGNC:26144): (partner and localizer of BRCA2) This gene encodes a protein that may function in tumor suppression. This protein binds to and colocalizes with the breast cancer 2 early onset protein (BRCA2) in nuclear foci and likely permits the stable intranuclear localization and accumulation of BRCA2. [provided by RefSeq, Jul 2008]
PALB2 Gene-Disease associations (from GenCC):
  • hereditary breast carcinoma
    Inheritance: AD Classification: DEFINITIVE Submitted by: Ambry Genetics
  • PALB2-related cancer predisposition
    Inheritance: AD Classification: DEFINITIVE Submitted by: ClinGen
  • Fanconi anemia complementation group N
    Inheritance: AR Classification: DEFINITIVE, STRONG Submitted by: Labcorp Genetics (formerly Invitae), G2P, ClinGen, Ambry Genetics
  • pancreatic cancer, susceptibility to, 3
    Inheritance: AD Classification: STRONG Submitted by: Labcorp Genetics (formerly Invitae), Genomics England PanelApp
  • Fanconi anemia
    Inheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet

Genome browser will be placed here

new If you want to explore the variant's impact on the transcript NM_024675.4, check out the Mutation Effect Viewer. This is especially useful for frameshift variants or if you want to visualize the effect of exon loss / intron retention.

Classification according to ACGS-UK Somatic Oncogenicity v2025

Classification was made for transcript:

Our verdict: Pathogenic. The variant received 11 points.

O1Established oncogenic variant
TSG gene: ClinVar germline P/LP ★★+ — Moderate (O1); O1 contributing sources (2.0 pts): ClinVar germline P/LP in TSG (★★)
O2Null variant in tumour suppressor gene
Frameshift/stop-gained, NMD predicted, LoF oncogenic mechanism — O2 very strong (+8); Use caution in the presence of multiple transcripts; Gene confirmed as TSG in CancerMine (TSG: 8 citations, oncogene: 1 citations, driver: 3 citations).; Frameshift/stop-gained. NMD predicted: true. LoF mechanism: true. Downstream pathogenic count: 0.
O3Absent or very rare in population
Very rare in gnomAD (popmax AF <0.01%) — O3 supporting; GnomAD effective popmax AF = 0.000017 — very rare (O3 supporting [+1])

Variant Effect in Transcripts

Automated classification analysis was done for transcript: NM_024675.4. You can select a different transcript below to see updated classification assignments.

RefSeq Transcripts

PALB2 NM_024675.4
MANE Select
HGVSc / HGVSpc.509_510delGAp.Arg170IlefsTer14
Exon rankExon 4 of 13
frameshift
Prot: NP_078951.2
PALB2 NM_001407296.1
HGVSc / HGVSpc.449_450delGAp.Arg150IlefsTer14
Exon rankExon 3 of 12
frameshift
Prot: NP_001394225.1
PALB2 NM_001407297.1
HGVSc / HGVSpc.509_510delGAp.Arg170IlefsTer14
Exon rankExon 4 of 12
frameshift
Prot: NP_001394226.1

Ensembl Transcripts

PALB2 ENST00000261584.9
TSL:1MANE Select
HGVSc / HGVSpc.509_510delGAp.Arg170IlefsTer14
Exon rankExon 4 of 13
frameshift
Prot: ENSP00000261584.4UniProt: Q86YC2
PALB2 ENST00000568219.5
TSL:1
HGVSc / HGVSpc.-377_-376delGA
Exon rankExon 4 of 13
5_prime_UTR
Prot: ENSP00000454703.2UniProt: H3BN63
PALB2 ENST00000561514.3
TSL:5
HGVSc / HGVSpc.515_516delGAp.Arg172IlefsTer14
Exon rankExon 4 of 13
frameshift
Prot: ENSP00000460666.3UniProt: A0AA52I2C1

Frequencies

Allele frequencies (AF), counts (AC/AN), homozygotes and coverage

Common (AF > 0.05 / Hom > 5)
Rare (AF ≤ 0.0001 / Hom ≤ 1)
Global population databases 6 sources
GnomAD3 genomes
AF: 0.0000131
AC:2
Hom:0
AN:152126
Cov:32
GnomAD2 exomes
AF: 0.0000358
AC:9
AN:251446
GnomAD4 exome
AF: 0.0000192
AC:28
Hom:0
AN:1461880
GnomAD4 genome
AF: 0.0000131
AC:2
Hom:0
AN:152126
Cov:32
TOPMed (Bravo)
AF: 0.0000113
ALFA (dbGaP/dbSNP Allele Frequency Aggregator)
AF: 0.00
AC:0
Hom:0
AN:17394
Showing 6 sources

Case/control cohorts

CohortCasesControls
AFACANAFACAN
Epi25
(Epilepsy)
0.0000477 241958 0.0000299 266888
SCHEMA
(Schizophrenia)
0.00 0113100 0.0000263 5190460
Showing 2 cohortsAllele count / allele number. AF is computed from the counts for ASC (not provided by the source).

ClinVar

ClinVar submissions
Significance:Pathogenic
Revision:criteria provided, multiple submitters, no conflicts
View on ClinVar
Pathogenic
VUS
Benign
Condition
17
-
-
not provided (17)
11
-
-
Familial cancer of breast (11)
8
-
-
Hereditary cancer-predisposing syndrome (8)
3
-
-
Breast-ovarian cancer, familial, susceptibility to, 5 (3)
2
-
-
Breast and/or ovarian cancer (2)
2
-
-
Malignant tumor of breast (2)
2
-
-
PALB2-related disorder (2)
1
-
-
autosomal dominant PALB2-related cancer predisposition (1)
1
-
-
Breast carcinoma (1)
1
-
-
Breast-ovarian cancer, familial, susceptibility to, 1 (1)
1
-
-
Carcinoma of pancreas (1)
1
-
-
Familial cancer of breast;C1835817:Fanconi anemia complementation group N;C3150547:Pancreatic cancer, susceptibility to, 3 (1)
1
-
-
Hereditary breast ovarian cancer syndrome (1)
1
-
-
Inherited breast cancer and ovarian cancer (1)
1
-
-
not specified (1)

Computational Scores

Mutation Taster
N/A0/200disease causing (ClinVar)
PhyloP100
Benign-0.018
Showing 2 of 2 scores

Splicing Scores

SpliceAI score (max)
Benign0.0
Details are displayed if max score is > 0.2
Showing 1 of 1 scores

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

MaxEntScan Visualizer can be used to analyze the impact of this mutation on the neighboring sequence.

MaveDB functional evidence

MaveDB is a public repository of laboratory assays that test the effect of thousands of variants at once — treat this as supporting research data and interpret it with great caution; it is not a clinical classification.

No MaveDB functional evidence found for this variant.

Publications

Other links and lift over

dbSNP: rs515726123;
hg19: chr16-23647356;
COSMIC: COSV108015612;
COSMIC: COSV108015612;
For research and educational, non-commercial use only. Not for clinical or diagnostic use. GeneBe does not provide medical advice. Data use for AI modeling is prohibited: if used, the cost is $0.001 per byte of downloaded uncompressed data.